Bullous pemphigoid and nivolumab: Dermatologic management to support and continue oncologic therapy-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Bullous pemphigoid and nivolumab: Dermatologic management to support and continue oncologic therapy

Published:2018-11 Issue: Volume:103 Page:284-286
ISSN:0959-8049
Container-title:European Journal of Cancer
language:en
Short-container-title:European Journal of Cancer

Author:

Panariello Luigia,Fattore Davide^ORCID,Annunziata Maria Carmela,Piantedosi Francovito,Gilli Marina,Fabbrocini Gabriella

Publisher

Elsevier BV

Subject

Cancer Research,Oncology

Reference6 articles.

1. Toxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodies;Topalian;Ann Oncol,2015

2. Immune checkpoint blockade in cancer therapy;Postow;J Clin Oncol,2015

3. Current diagnosis and management of immune related adverse events (irAEs) induced by immune checkpoint inhibitor therapy;Kumar;Front Pharmacol,2017

4. A review of bullous pemphigoid associated with PD-1 and PD-L1 inhibitors;Lopez;Int J Dermatol,2018

5. Bullous pemphigoid associated with nivolumab, a programmed cell death 1 protein inhibitor;Kwon;J Eur Acad Dermatol Venereol,2017

Cited by 17 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Perspectives on Psoriasiform Adverse Events from Immune Checkpoint Inhibitors: Lessons Learned from Our Practice;Medicina;2024-02-22

2. Atezolizumab-Induced Acrodermatitis and Pustular Psoriasis in a Patient with Non-Small Cell Lung Cancer: A Rare Case Report;Case Reports in Dermatology;2024-02-21

3. A Retrospective, Single-Institution Experience of Bullous Pemphigoid as an Adverse Effect of Immune Checkpoint Inhibitors;Cancers;2022-11-05

4. Scleroderma-like Syndrome in the Setting of Pembrolizumab Therapy for Non-Small Cell Lung Cancer: Diagnosis and Dermatologic Management;Case Reports in Dermatology;2022-08-19

5. Association of Bullous Pemphigoid With Immune Checkpoint Inhibitor Therapy in Patients With Cancer;JAMA Dermatology;2022-08-01

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3